DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Boniva (Ibandronate Sodium) - Published Studies

 
 



Boniva Related Published Studies

Well-designed clinical trials related to Boniva (Ibandronic Acid)

Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). [2005.12]

Well-designed clinical trials possibly related to Boniva (Ibandronic Acid)

Effect of ibandronate on spontaneous osteonecrosis of the knee: a randomized, double-blind, placebo-controlled trial. [2014]

Intravenous ibandronate or sodium-fluoride--a 3.5 years study on bone density and fractures in Crohn's disease patients with osteoporosis. [2011.06]

Bones and Crohn's: no benefit of adding sodium fluoride or ibandronate to calcium and vitamin D. [2011.01.21]

Increases in hip and spine bone mineral density are predictive for vertebral antifracture efficacy with ibandronate. [2010.10]

Treatment of osteoporosis after liver transplantation with ibandronate. [2010.07]

Regional distribution of spine and hip QCT BMD responses after one year of once-monthly ibandronate in postmenopausal osteoporosis. [2010.06]

[Monthly ibandronate attachment to Mexican and Chilean women with osteoporosis, with or without a biofeedback strategy]. [2010.06]

Infusion of ibandronate once every 3 months effectively decreases bone resorption markers and increases bone mineral density in Chinese postmenopausal osteoporotic women: a 1-year study. [2010.05]

The utility of changes in serum levels of C-terminal telopeptide of type I collagen in predicting patient response to oral monthly ibandronate therapy. [2010.04]

Efficacy and safety of monthly ibandronate in men with low bone density. [2010.04]

Risk reduction of non-vertebral fractures with intravenous ibandronate: post-hoc analysis from DIVA. [2010.03]

Effects of intermittent intravenous ibandronate injections on bone quality and micro-architecture in women with postmenopausal osteoporosis: the DIVA study. [2010.03]

Ibandronate increases cortical bone density in patients with systemic lupus erythematosus on long-term glucocorticoid. [2010]

The utility of changes in serum levels of C-terminal telopeptide of type I collagen in predicting patient response to oral monthly ibandronate therapy. [2010]

Efficacy and safety of monthly ibandronate in men with low bone density. [2010]

Risk reduction of non-vertebral fractures with intravenous ibandronate: post-hoc analysis from DIVA. [2010]

Effects of intermittent intravenous ibandronate injections on bone quality and micro-architecture in women with postmenopausal osteoporosis: the DIVA study. [2010]

Comparison of monthly ibandronate versus weekly risedronate in preference, convenience, and bone turnover markers in Korean postmenopausal osteoporotic women. [2009.11]

Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer. [2009.11]

Monthly ibandronate suppresses serum CTX-I within 3 days and maintains a monthly fluctuating pattern of suppression. [2009.09]

Ibandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: a randomized double-blind, placebo-controlled trial. [2009.07]

Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study. [2009.04]

Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss. [2009.03]

Oral ibandronate preserves trabecular microarchitecture: micro-computed tomography findings from the oral iBandronate Osteoporosis vertebral fracture trial in North America and Europe study. [2009.01]

Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis. [2009.01]

Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. [2008.10.01]

An open-label pilot trial of ibandronate for complex regional pain syndrome. [2008.10]

Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension. [2008.08]

Treatment of reduced bone density with ibandronate in dialysis patients. [2008.07]

Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study. [2008.07]

Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II). [2008.05]

Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. [2008.03]

Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies. [2008.03]

Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. [2008.01]

Cost effectiveness of ibandronate for the prevention of fractures in inflammatory bowel disease-related osteoporosis: cost-utility analysis using a Markov model. [2008]

Local peroperative treatment with a bisphosphonate improves the fixation of total knee prostheses: a randomized, double-blind radiostereometric study of 50 patients. [2007.12]

Ibandronate is effective in preventing skeletal events in patients with bone metastases from colorectal cancer. [2007.11]

Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases. [2007.07]

Rinsing morcellised bone grafts with bisphosphonate solution prevents their resorption. A prospective randomised double-blinded study. [2006.08]

Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. [2006.08]

Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: phase III trial results. [2006.07]

Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. [2006.06]

Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. [2006.05]

Modeling of serum C-telopeptide levels with daily and monthly oral ibandronate in humans. [2006.04]

Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen. [2006.04]

Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis. [2005.11]

Safety and tolerability of oral daily and intermittent ibandronate are not influenced by age. [2005.10]

Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study. [2005.09]

Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. [2005.08]

Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials. [2005.06]

Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE. [2005.03]

Effective doses of ibandronate do not influence the 3-year progression of aortic calcification in elderly osteoporotic women. [2005.02]

[Ibandronate as a new therapeutic agent for osteoporosis.] [2005.01]

Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. [2004.10]

Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. [2004.10]

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. [2004.08]

Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. [2004.07]

Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. [2004.05]

Efficacy and safety of ibandronate given by intravenous injection once every 3 months. [2004.05]

Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. [2004.05]

Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. [2004.03.22]

Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study. [2004.03]

Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis. [2004.01]

Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis. [2003.10]

Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women. [2003.10]

Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. [2003.09]

Oral weekly ibandronate prevents bone loss in postmenopausal women. [2003.08]

Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate. [2003.08]

Dose dependent effects on bone resorption and formation of intermittently administered intravenous ibandronate. [2003.07]

Oral ibandronate: changes in markers of bone turnover during adequately dosed continuous and weekly therapy and during different suboptimally dosed treatment regimens. [2003.06]

The efficacy of 48-week oral ibandronate treatment in postmenopausal osteoporosis when taken 30 versus 60 minutes before breakfast. [2003.04]

Therapy of osteoporosis in patients with Crohn's disease: a randomized study comparing sodium fluoride and ibandronate. [2003.03.15]

Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma. [2003.01]

Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type II degradation products. [2002.06]

Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. [2002.05.01]

Association between pharmacokinetics of oral ibandronate and clinical response in bone mass and bone turnover in women with postmenopausal osteoporosis. [2002.01]

Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. [2001.10]

Effect of ibandronate on bone loss and renal function after kidney transplantation. [2001.07]

Short- and long-term effects of ibandronate treatment on bone turnover in Paget disease of bone. [2000.05]

Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy. [1999.10]

Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease. [1999.03]

Bone densitometry: a new, highly responsive region of interest in the distal forearm to monitor the effect of osteoporosis treatment. [1999]

Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides. [1998.11]

Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: prediction of bone mass changes during treatment. [1998.05]

Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. [1997.10]

Implementation of an osteoporosis research program with a mobile dual-energy X-ray absorptiometry unit: the Montana/Wyoming experience. [1997]

Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia. [1997]

The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study. [1996.11]

Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. [1996.01]

Other research related to Boniva (Ibandronic Acid)

Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial. [2014]

Bioequivalence study of two formulations of ibandronic acid 150-mg film-coated tablets in healthy volunteers under fasting conditions: a randomized, open-label, three-way, reference-replicated crossover study. [2014]

Renal function changes and NHS resource use in breast cancer patients with metastatic bone disease treated with IV zoledronic acid or oral ibandronic acid: a four-centre non-interventional study. [2010.03]

Oral versus intravenous ibandronic acid: a comparison of treatment options for metastatic bone disease. [2008.12]

Managing neoplastic bone disease with ibandronic acid: a preclinical and clinical data update. [2008.12]

Oral versus intravenous ibandronic acid: a comparison of treatment options for metastatic bone disease. [2008.05.27]

Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial. [2006]

Eletriptan: a review of its use in the acute treatment of migraine. [2006]

Oral ibandronic acid. [2005.02]

Other possibly related research studies

Combination ibandronate and radiotherapy for the treatment of bone metastases: clinical evaluation and radiologic assessment. [2007.01.01]

Bisphosphonates prevent experimental vascular calcification: Treat the bone to cure the vessels? [2006.11]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017